1. Home
  2. MBWM vs NUVB Comparison

MBWM vs NUVB Comparison

Compare MBWM & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBWM
  • NUVB
  • Stock Information
  • Founded
  • MBWM 1997
  • NUVB 2018
  • Country
  • MBWM United States
  • NUVB United States
  • Employees
  • MBWM N/A
  • NUVB N/A
  • Industry
  • MBWM Major Banks
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBWM Finance
  • NUVB Health Care
  • Exchange
  • MBWM Nasdaq
  • NUVB Nasdaq
  • Market Cap
  • MBWM 732.4M
  • NUVB 679.9M
  • IPO Year
  • MBWM 1997
  • NUVB N/A
  • Fundamental
  • Price
  • MBWM $44.03
  • NUVB $1.81
  • Analyst Decision
  • MBWM Buy
  • NUVB Strong Buy
  • Analyst Count
  • MBWM 2
  • NUVB 6
  • Target Price
  • MBWM $55.00
  • NUVB $8.33
  • AVG Volume (30 Days)
  • MBWM 68.1K
  • NUVB 3.1M
  • Earning Date
  • MBWM 04-15-2025
  • NUVB 03-06-2025
  • Dividend Yield
  • MBWM 3.21%
  • NUVB N/A
  • EPS Growth
  • MBWM N/A
  • NUVB N/A
  • EPS
  • MBWM 4.93
  • NUVB N/A
  • Revenue
  • MBWM $224,075,000.00
  • NUVB $7,873,000.00
  • Revenue This Year
  • MBWM $8.04
  • NUVB $47.99
  • Revenue Next Year
  • MBWM $4.10
  • NUVB $551.81
  • P/E Ratio
  • MBWM $9.10
  • NUVB N/A
  • Revenue Growth
  • MBWM 2.79
  • NUVB N/A
  • 52 Week Low
  • MBWM $33.46
  • NUVB $1.71
  • 52 Week High
  • MBWM $52.98
  • NUVB $3.97
  • Technical
  • Relative Strength Index (RSI)
  • MBWM 40.15
  • NUVB 36.74
  • Support Level
  • MBWM $43.59
  • NUVB $1.85
  • Resistance Level
  • MBWM $45.69
  • NUVB $2.04
  • Average True Range (ATR)
  • MBWM 1.27
  • NUVB 0.16
  • MACD
  • MBWM 0.07
  • NUVB -0.01
  • Stochastic Oscillator
  • MBWM 32.96
  • NUVB 1.81

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It provides a variety of commercial banking services to individuals, businesses, governmental units, and other institutions. It provides banking services offering deposit products including checking, savings, and term certificate accounts, and lending products including commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: